Taking Buscopan alongside Mounjaro: what you should know

The scenario most people are in when they search this

You started Mounjaro a few weeks ago (or you've just moved up to a higher dose) and your stomach is protesting. Cramping, bloating, a general sense of digestive unease. You've got a packet of Buscopan in the medicine drawer, and you'd like to know whether reaching for it is sensible or whether it complicates your treatment. It's a genuinely reasonable question, and the fact that you're checking before taking anything speaks well of you.

Gastrointestinal side effects are the most frequently reported effects of tirzepatide across clinical trial data and real-world use. The NHS medicines page for tirzepatide lists nausea, constipation, diarrhoea and stomach discomfort among the common effects, and notes these tend to be most noticeable in the first few days after starting or increasing a dose, generally settling as the body adjusts. So the timing of your symptoms is likely not coincidence.

Understanding why Mounjaro affects the gut helps frame the Buscopan question. Tirzepatide acts on two gut-hormone receptors, GIP and GLP-1, and part of that action involves slowing the rate at which the stomach empties into the small intestine. That slowing is partly responsible for the fullness signal that supports weight loss, but it can also produce the cramping and nausea some people feel, particularly early on.

What Buscopan does, and how Mounjaro's mechanism complicates the picture

Buscopan works by relaxing the smooth muscle lining the gut wall, reducing painful spasm. For cramps caused by irritable bowel, trapped wind or short-term gut upset, it can offer real relief. On its own, it is generally well tolerated and is not flagged as having a significant interaction with tirzepatide in clinical reference sources.

The complication is more practical than pharmacological. Because Mounjaro delays gastric emptying, any oral medicine taken in the same window may sit in the stomach longer before being absorbed. For a medicine like Buscopan, which is taken as needed for acute cramps, this is unlikely to cause harm, but it does mean the relief may take longer to arrive than you'd expect from past experience. It also means that if you were relying on precise absorption timing for any other oral medicine, that's worth flagging to your prescriber. Our page on Mounjaro and HRT covers why oral versus transdermal routes matter for that particular combination, if that's relevant to you.

There is a second consideration. Buscopan also has mild anticholinergic effects, meaning it can reduce gut motility more broadly. If Mounjaro has already slowed your digestive transit, adding an antispasmodic on top of that could compound constipation in some people. This isn't a reason to avoid Buscopan outright, but it's worth being alert to, especially if constipation rather than craming is already your main complaint.

When gut symptoms on Mounjaro need more than Buscopan

Mild cramps and occasional bloating during the early phase of tirzepatide treatment are common and usually self-limiting. Practical measures (eating smaller portions, avoiding rich or fatty foods, staying well hydrated, and giving each dose step time to settle) help more people than reaching straight for medication.

Some symptoms, though, should prompt medical attention rather than self-management with an OTC product. The MHRA issued a Drug Safety Update in January 2026 highlighting that acute pancreatitis, while uncommon, is a known risk with GLP-1 medicines: severe or persistent stomach pain that radiates toward the back, with or without vomiting, should not be attributed to ordinary GI upset and warrants urgent assessment. You can find that safety communication and report any suspected effects via the MHRA Yellow Card scheme.

Persistent cramping that doesn't settle within a couple of weeks, symptoms severe enough to prevent eating or drinking, or anything that feels different from ordinary digestive discomfort, all of these are worth raising with a prescriber rather than managing independently. If you're on a tirzepatide programme through nume and something doesn't feel right, our aftercare team is available seven days a week.

For anyone curious about how Mounjaro interacts with other health conditions (IBS and Mounjaro is a question we see often, given the overlap in gut symptoms) there's more detail on the site. Those with questions about the broader treatment picture can find a full overview on our Mounjaro information page.

Practical steps if you're managing gut symptoms on tirzepatide

A short course of Buscopan for acute cramping is unlikely to be harmful while you're on Mounjaro, and it is not listed as a contraindicated combination. But a few principles are worth keeping in mind.

First, tell your prescriber or pharmacist you're on tirzepatide before taking any new medicine, even an OTC one. They can give personalised advice based on your full picture, something a general article cannot. Second, if you do take Buscopan, don't be surprised if it takes longer than usual to work; the slowed gastric emptying can delay onset. Third, monitor for constipation: if that's already a side effect for you, an antispasmodic that further reduces gut motility may not be the most helpful choice, and a prescriber might suggest alternatives. It's also worth knowing that some people notice changes in other areas of their health while on tirzepatide, and our page on Mounjaro and ED explores one such concern that comes up in consultations more often than you might expect.

Thinking about whether Mounjaro is the right treatment for your situation overall? Our clinical team reviews every consultation personally, you can find out more about the prescribers behind the service on the clinical team page. If you'd like to explore whether tirzepatide is suitable for you, this guide on suitability covers the eligibility criteria in detail. There's also a transparent look at Mounjaro costs in the UK if you're weighing up your options. When you're ready, you can check your eligibility and start a free consultation with our prescribers.